A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
|Videos|May 20, 2015
What Lessons Have Been Learned from High Cost Hepatitis C Drugs?
Author(s)Davy James, Managing Editor
Marc O'Connor, Chief Operating Officer of Curant Health, discusses the main takeaways from the impact of hepatitis C drugs on specialty pharmacy.
Advertisement
Marc O'Connor, Chief Operating Officer of Curant Health, discusses the main takeaways from the impact of hepatitis C drugs on specialty pharmacy.
This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
Advertisement
Related to this article
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5